Výsledky vyhledávání

Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases

Autor: Todd Dumas, Stephen Jolles, Martin J. Wolfsegger, Seth Berry, Leman Yel, Barbara McCoy

Publikováno v: International Immunopharmacology. 71:404-410

Background\ud \ud Immunoglobulin (IG) replacement therapy in patients with primary immunodeficiency diseases (PID) can be administered daily to every 2 weeks subcutaneously (SCIG) or every 3 or 4 weeks intravenously (IVIG).\ud \ud \ud Objectives\ud \

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98af7568337d00a4099d3a301e1a4007
https://doi.org/10.1016/j.intimp.2019.03.034

Zobrazit plný text záznamu

Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases

Autor: Todd Dumas, Seth Berry, Barbara McCoy, Zhaoyang Li, Leman Yel

Publikováno v: International immunopharmacology. 100

BACKGROUND The pharmacokinetics of Ig20Gly, a 20% subcutaneous immunoglobulin (IG) therapy, is well characterized in IG-experienced patients with primary immunodeficiency diseases (PID). Data from IG-naive patients are limited. OBJECTIVE Simulate ser

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::386e0fab9ec0a7138d37735d0dc9599e
https://pubmed.ncbi.nlm.nih.gov/34601202

Zobrazit plný text záznamu

Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458)

Autor: Todd Dumas, Tong Lin, Josh Kaullen, Katie Zomorodi, Jeffrey A. Silverman, Mi Rim Choi, Seth Berry

Publikováno v: Clinical pharmacology in drug development. 10(12)

JZP-458 is a recombinant Erwinia asparaginase produced using a novel Pseudomonas fluorescens expression platform that yields an enzyme expected to lack immunologic cross-reactivity to Escherichia coli-derived asparaginases. It is being developed as p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13d8a410ea14a021316d8d88de6443a1
https://pubmed.ncbi.nlm.nih.gov/34310867

Zobrazit plný text záznamu

Population Pharmacokinetic Modeling of Intravenous Asparaginase Erwinia Chrysanthemi: Impact of Varied Infusion Rates on Exposure

Autor: Todd Dumas, Katie Zomorodi, Mark Eller, Curtis Johnston, Seth Berry

Publikováno v: Blood. 128:1631-1631

Introduction: Asparaginase Erwinia chrysanthemi (Erwinia), an asparagine-specific enzyme indicated as a component of a multiagent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypers

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d615f6a068f7cc07f93dbba6ea9fb1f1
https://doi.org/10.1182/blood.v128.22.1631.1631

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání